pipette
ESEspañol

Osimertinib, platinum, and etoposide for patients with metastatic EGFR / TP53 / RB1 -mutant lung cancers at risk for histological transformation

Lena Morrill Gavarró, Monica F. Chen, Àlvaro Quintanal-Villalonga, Yufei Deng, Liancheng Lu, Britney Forsyth, Sahil Sahni, Eric G. Sun, Swanand Rakhade, Rania Gaber Mohamed Aly, Meng Wang, Amin H. Sabet, P Solanki, Christina E. Wilson, Natasha Rekhtman, Sam E. Tischfield, Jake June-Koo Lee, Khadeja A. Moses, Linda Su Hyun Ahn, Clare Wilhelm, Amanda Pupo, Christina J. Falcon, Andrea Arfè, Katherine S. Panageas, Mark G. Kris, Parvathy Manoj, Ignas Masilionis, Ojasvi Chaudhary, Ronan Chaligné, Esther Redín, Eric E. Gardner, Xinjun Wang, Dana Pe’er, Charles M. Rudin, Joseph Minhow Chan, Helena Alexandra Yu

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
Despite the addition of SCLC-directed chemotherapy, nearly half of patients (5 of 11) underwent SCLC transformation, with median progression-free survival of 11 months and overall survival of 33 months.

Appeared: Friday, November 13. Science Translational Medicine. Peer-reviewed journal.

DOI: 10.1126/scitranslmed.aee6618